FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Arno Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-42.

AR-42 is an orally available, novel, potent, small molecule that modifies the acetylation of histones and other molecules, and is a targeted inhibitor of the Pan-DAC and Akt pathways. HDAC inhibitors disrupt HDAC-PP1 complexes and cause signaling kinase dephosphorylation. In preclinical studies, AR-42 has demonstrated greater potency and a competitive profile in tumors when compared with vorinostat (also known as SAHA and marketed as Zolina (R) by Merck), the leading marketed histone deacetylase inhibitor. Arno in-licensed the exclusive worldwide rights to AR-42 from The Ohio State University.